Johanna M Seddon1, Rachel E Silver2, Manlik Kwong3, Bernard Rosner4. 1. Ophthalmic Epidemiology and Genetics Service, New England Eye Center, Tufts Medical Center, Boston, Massachusetts, United States 2Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, United States 3Sackler School of Gra. 2. Ophthalmic Epidemiology and Genetics Service, New England Eye Center, Tufts Medical Center, Boston, Massachusetts, United States. 3. Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States. 4. Channing Division of Network Medicine, Harvard Medical School, Harvard University, Boston, Massachusetts, United States.
Abstract
PURPOSE: To determine the association between genetic variants and transition to advanced age-related macular degeneration (AMD), and to develop a predictive model and online application to assist in clinical decision making. METHODS: Among 2951 subjects in the Age-Related Eye Disease Study, 834 progressed from no AMD, early AMD, or intermediate AMD to advanced disease. Survival analysis was used to assess which genetic, demographic, environmental, and macular covariates were independently associated with progression. Attributable risk, area under the curve statistics (AUCs), and reclassification odds ratios (ORs) were calculated. Split-sample validation was performed. An online risk calculator was developed and is available in the public domain at www.seddonamdriskscore.org. RESULTS: Ten genetic loci were independently associated with progression, including newly identified rare variant C3 K155Q (hazard ratio: 1.7, 95% confidence interval: 1.2-2.5, P = 0.002), three variants in CFH, and six variants in ARMS2/HTRA1, CFB, C3, C2, COL8A1, and RAD51B. Attributable risk calculations revealed that 80% of incident AMD is attributable to genetic factors, adjusting for demographic covariates and baseline macular phenotypes. In a model including 10 genetic loci, age, sex, education, body mass index, smoking, and baseline AMD status, the AUC for progression to advanced AMD over 10 years was 0.911. Split-sample validation showed a similar AUC (0.907). Reclassification analyses indicated that subjects were categorized into a more accurate risk category if genetic information was included (OR 3.2, P < 0.0001). CONCLUSIONS: Rare variant C3 K155Q was independently associated with AMD progression. The comprehensive model may be useful for identifying and monitoring high-risk patients, selecting appropriate therapies, and designing clinical trials.
PURPOSE: To determine the association between genetic variants and transition to advanced age-related macular degeneration (AMD), and to develop a predictive model and online application to assist in clinical decision making. METHODS: Among 2951 subjects in the Age-Related Eye Disease Study, 834 progressed from no AMD, early AMD, or intermediate AMD to advanced disease. Survival analysis was used to assess which genetic, demographic, environmental, and macular covariates were independently associated with progression. Attributable risk, area under the curve statistics (AUCs), and reclassification odds ratios (ORs) were calculated. Split-sample validation was performed. An online risk calculator was developed and is available in the public domain at www.seddonamdriskscore.org. RESULTS: Ten genetic loci were independently associated with progression, including newly identified rare variant C3 K155Q (hazard ratio: 1.7, 95% confidence interval: 1.2-2.5, P = 0.002), three variants in CFH, and six variants in ARMS2/HTRA1, CFB, C3, C2, COL8A1, and RAD51B. Attributable risk calculations revealed that 80% of incident AMD is attributable to genetic factors, adjusting for demographic covariates and baseline macular phenotypes. In a model including 10 genetic loci, age, sex, education, body mass index, smoking, and baseline AMD status, the AUC for progression to advanced AMD over 10 years was 0.911. Split-sample validation showed a similar AUC (0.907). Reclassification analyses indicated that subjects were categorized into a more accurate risk category if genetic information was included (OR 3.2, P < 0.0001). CONCLUSIONS: Rare variant C3 K155Q was independently associated with AMD progression. The comprehensive model may be useful for identifying and monitoring high-risk patients, selecting appropriate therapies, and designing clinical trials.
Authors: Julian Maller; Sarah George; Shaun Purcell; Jes Fagerness; David Altshuler; Mark J Daly; Johanna M Seddon Journal: Nat Genet Date: 2006-08-27 Impact factor: 38.330
Authors: M H Gail; L A Brinton; D P Byar; D K Corle; S B Green; C Schairer; J J Mulvihill Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: Gonçalo R Abecasis; David Altshuler; Adam Auton; Lisa D Brooks; Richard M Durbin; Richard A Gibbs; Matt E Hurles; Gil A McVean Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Johanna M Seddon; Peter J Francis; Sarah George; Dennis W Schultz; Bernard Rosner; Michael L Klein Journal: JAMA Date: 2007-04-25 Impact factor: 56.272
Authors: Johanna M Seddon; Robyn Reynolds; Julian Maller; Jesen A Fagerness; Mark J Daly; Bernard Rosner Journal: Invest Ophthalmol Vis Sci Date: 2008-12-30 Impact factor: 4.799
Authors: Yi Yu; Erin K Wagner; Eric H Souied; Sanna Seitsonen; Ilkka J Immonen; Paavo Häppölä; Soumya Raychaudhuri; Mark J Daly; Johanna M Seddon Journal: Hum Mol Genet Date: 2016-12-01 Impact factor: 6.150
Authors: Qi Yan; Ying Ding; Yi Liu; Tao Sun; Lars G Fritsche; Traci Clemons; Rinki Ratnapriya; Michael L Klein; Richard J Cook; Yu Liu; Ruzong Fan; Lai Wei; Gonçalo R Abecasis; Anand Swaroop; Emily Y Chew; Daniel E Weeks; Wei Chen Journal: Hum Mol Genet Date: 2018-03-01 Impact factor: 6.150
Authors: Frank G Holz; Srinivas R Sadda; Brandon Busbee; Emily Y Chew; Paul Mitchell; Adnan Tufail; Christopher Brittain; Daniela Ferrara; Sarah Gray; Lee Honigberg; Jillian Martin; Barbara Tong; Jason S Ehrlich; Neil M Bressler Journal: JAMA Ophthalmol Date: 2018-06-01 Impact factor: 7.389